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Abstract: Background: Traffic-related air pollution (TRAP) refers to the wide range of air pollutants
emitted by traffic that are dispersed into the ambient air. Emerging evidence shows that TRAP
can increase asthma incidence in children. Living with asthma can carry a huge financial burden
for individuals and families due to direct and indirect medical expenses, which can include costs
of hospitalization, medical visits, medication, missed school days, and loss of wages from missed
workdays for caregivers. Objective: The objective of this paper is to estimate the economic impact of
childhood asthma incident cases attributable to nitrogen dioxide (NO2), a common traffic-related air
pollutant in urban areas, in the United States at the state level. Methods: We calculate the direct and
indirect costs of childhood asthma incident cases attributable to NO2 using previously published
burden of disease estimates and per person asthma cost estimates. By multiplying the per person
indirect and direct costs for each state with the NO2-attributable asthma incident cases in each state,
we were able to estimate the total cost of childhood asthma cases attributable to NO2 in the United
States. Results: The cost calculation estimates the total direct and indirect annual cost of childhood
asthma cases attributable to NO2 in the year 2010 to be $178,900,138.989 (95% CI: $101,019,728.20–
$256,980,126.65). The state with the highest cost burden is California with $24,501,859.84 (95% CI:
$10,020,182.62–$38,982,261.250), and the state with the lowest cost burden is Montana with $88,880.12
(95% CI: $33,491.06–$144,269.18). Conclusion: This study estimates the annual costs of childhood
asthma incident cases attributable to NO2 and demonstrates the importance of conducting economic
impacts studies of TRAP. It is important for policy-making institutions to focus on this problem by
advocating and supporting more studies on TRAP’s impact on the national economy and health,
including these economic impact estimates in the decision-making process, and devising mitigation
strategies to reduce TRAP and the population’s exposure.
Keywords: air pollution; asthma; cost of illness; traffic emissions; public health; economics; pediatric
asthma; traffic related air pollution
1. Introduction
In the United States (U.S.), asthma is one of the most common chronic diseases, af-
fecting approximately 5,530,131 children and 24,753,379 adults and children in 2018 [1,2].
Asthma presents itself as repeated episodes of wheezing, breathlessness, chest tightness,
and nighttime or early morning coughing [3]. An individual’s asthma severity can vary.
Asthma severity refers to the intensity of the disease process, and is categorized into two
types: intermittent severity and persistent severity [4]. Intermittent severity includes peo-
ple with asthma that is well-controlled without long-term control medication [4]. Persistent
severity includes people with well-controlled asthma with long-term control medications
and people with uncontrolled asthma who are not on long-term control medication [4].
Int. J. Environ. Res. Public Health 2021, 18, 7864. https://doi.org/10.3390/ijerph18157864 https://www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2021, 18, 7864 2 of 21
Nearly 60% of children with current asthma have persistent asthma and 40% have inter-
mittent asthma [4]. Asthma may develop as a result of various risk factors, including
family history, viral respiratory infections, allergies, smoking, obesity, and exposure to
environmental contaminants, including traffic-related air pollution (TRAP) [5,6]. This
paper focuses on the latter risk factor: the association with TRAP.
TRAP refers to the wide range of air pollutants emitted by traffic through combustion
and non-combustion routes and dispersed into the ambient air. TRAP is a major source
of ambient air pollution in urban areas and cities [6,7]. Traffic emits pollutants including
carbon monoxide (CO), nitrogen dioxide (NO2), nitrogen oxides (NOx), particulate matter
with a diameter less than 2.5 micrometers (PM2.5), particulate matter with a diameter
less than 10 micrometers (PM10), benzene, lead, and sulfur, and others [7], and leads
to the formation of secondary by-products and aerosols (e.g., ozone (O3) and nitrates).
Other pollutants include organic and chemical material from tire wear, brake wear, and
resuspended dust [8]. In this paper, we focus on the cost impacts of childhood asthma
caused by NO2, as it is a pollutant which is relatively specific to TRAP in urban areas and
cities [9].
Air pollution is an environmental risk factor that was proven to exacerbate pre-
existing asthma cases, but in the past, it was not believed to lead to the onset of new asthma
cases [10–12]. However, an increased understanding of interactions between genetic and
environmental factors, and an ever-growing evidence base have shown that TRAP exposure
may lead to the development of asthma in children [7,9,13,14]. As emerging evidence
shows the effect TRAP can have on asthma incidence, it is important to understand how
expansive that effect is. The impact of TRAP on childhood asthma in the U.S. has been
quantified by a 2019 study, which estimated the number and percentage of childhood
asthma incident cases attributable to TRAP in 2000 and 2010 [15]. Th study concluded
that, on average, the percentage of childhood asthma incident cases attributable to TRAP
in the contiguous U.S. may range between 18% (NO2) and 42% (PM10), depending on
the pollutant selected to represent the TRAP mixture, with NO2 being more specific [15].
These results indicated that TRAP may be responsible for a large number of preventable
childhood asthma cases [15]. Another study in 2020 quantified the number of childhood
asthma incident cases attributable to NO2 in the U.S., citing NO2 as a more specific marker
of the TRAP mixture [16]. Using state-level incidence rates, Khreis et al. [16] estimated
that a total of 134,166 (95% CI: 75,177–193,327) childhood asthma incident cases were
attributable to NO2, accounting for 17.6% of all childhood asthma incident cases [16].
Khreis et al. [17] also estimated that between 7% to 12% of all childhood asthma cases in
Bradford, United Kingdom were attributable to TRAP [17].
Living with asthma can carry a huge financial burden for individuals and families.
Direct costs such as costs for alternative treatment, medications, primary care consultations,
hospital emergency and outpatient attendance, ambulance and other transportation, and
hospital admissions, in addition to indirect costs such as missing school and workdays,
contribute to asthma’s financial burden [18]. In 2007, asthma resulted in more than $56
billion in medical costs, lost school and workdays, and early death in the U.S. for all
cases [19]. In 2013, the number of asthma-related missed school days was 13.8 million [20].
In 2015, the total number of missed school days among children with asthma ranged from
9020 days to 617,980 days across the 50 U.S. states and Washington, District of Columbia
(D.C.) [21]. The cost range by state for school absenteeism ranges from $1.4 million to
$116.5 million, while the cost for missed school and workdays ranges from $4.4 million
to $344.9 million by state [21]. Furthermore, people with asthma experience over 497,000
hospitalizations annually in the U.S. collectively [22]. The average per person annual
medical costs for asthma is estimated to be $3300 for the entire population while the annual
medical costs per child were estimated to be $1740 [23]. Notably, costs vary widely by state.
The Nurmagambetov et al. [21] study found that the total medical and absenteeism costs
for childhood asthma in 2015 ranged from $7.7 million in Wyoming to $488.1 million in
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California. The total costs (for children and adults) ranged from $65.1 million in Wyoming
to $3718.1 million in California [21].
In this study, we focus on estimating the economic burden of childhood asthma
incident cases attributable to NO2. We will use previous estimates of childhood asthma
incident cases attributable to NO2 in the U.S. from Khreis et al. [16] to determine its
economic impact. While there are previous studies looking at the economic burden of
pediatric and adult asthma nationally or by state [21,23,24], few studies specifically address
the economic burden of childhood asthma cases attributable to air pollution in the U.S.
Those that exist are either conducted in small communities or cities, different countries,
address other health issues related to environmental contaminants, or focus on only a
few cost variables (e.g., only hospitalization costs) (Table 1). Some previous studies were
restrictive in terms of location; for example, they were set in a single county, such as Los
Angeles County, or in cities, such as Shanghai, Riverside, and Long Beach [25,26]. One
study examined the association between sub-chronic exposure of six outdoor air pollutants
(PM2.5, PM10, O3, NO2, SO2, CO) and pediatric asthma hospitalization length of stay,
charges, and costs, but it did not follow a burden of disease (BoD) assessment methodology
like this work [27]. The methodology of Roy et al. [27] is also very different than our study,
as we built on a previously published BoD assessment and published direct and indirect
asthma costs by state. Our study fills a gap in the literature with an overarching assessment
of the full economic impacts of childhood asthma incident cases attributable to NO2, at the
U.S. state level.
Our study is in a unique position to conduct an overarching assessment of the eco-
nomic impacts of pediatric asthma incidence attributable to NO2 in the U.S. We aim to
monetize childhood asthma incidence in the U.S. specifically attributable to NO2 at the
state level, building on the most recent and comprehensive BoD and economic impact as-
sessment work [16,21]. We will calculate both indirect and direct costs and will provide an
economic analysis, showing the total cost of childhood asthma incident cases attributable
to NO2 in each state using the most holistic definitions for the cost of illness.
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Table 1. Summary of previous studies.
Previous
Review Previous Review Scope Pollutants Studied Region Studied Population
Years
Studied Key Differences to Our Study
[26]
• Estimated outdoor air pollution’s
short-term effect on daily asthma-related
patient visits and their economic costs.
• Calculated economic cost of patient visits
by pollutant.
SO2, CO, NO2, PM10,
O3, and PM2.5
Shanghai, China
The patient pool was




• Scope focuses only on the short-term effect
of air pollution.
• Limited region study to Shanghai, China.
• Patient age not specified to specific group.
• Only analyzed the cost variable of asthma
patient visits.
[25]
• Estimates the cost of childhood asthma
caused by near roadway pollution
(NRP).
• Calculated the direct cost of medical
goods and services, and indirect costs of
caregivers’ lost wages, as well as
willingness to pay.








• Studied hypothetical scenarios involving a
decrease in pollution and a decrease or
increase in population density within 75 m
of a major roadway.
• Limited region study to Los Angeles
County.
• Analyzed the cost effect of the willingness
to pay and only looked at the indirect cost
of the caregiver and not the child.
• Analyzed NRP, NO2, and O3 exposures.
[28]
• Estimates the cost of childhood asthma
cases attributable to air pollution.
• Calculated the direct and indirect cost
and the cost of bronchitis episodes in
addition to asthma cost.
• Costs are in 2010 dollars.
NO2 and O3
Riverside and Long Beach,
California.




• Studied NO2 and O3.
• Limited region to two California cities.
• Looked specifically at the unique economic
effect of bronchitis episodes had on costs in
addition to asthma.
• Study is not specified to a year.
[27]
• Examines the association between
sub-chronic (the authors defined the
following exposures: an exposure
duration of less than 14 days is acute,
more than 14 days up to one year is
sub-chronic, and greater than one year is
chronic) exposure (in between acute and
chronic) to six outdoor air pollutants
with both costs and length of stay of









• Scope focuses only on direct costs of
pediatric asthma hospitalizations.
• Studied PM2.5, PM10, O3, NO2, SO2, and
CO.
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2. Materials and Methods
2.1. Overview
In this study, we examine the economic impact of childhood asthma incident cases
attributable to NO2. We conducted an economic study by finding the cost of a single child-
hood asthma case in each state and multiplying it with the number of childhood asthma
incident cases attributable to NO2 in each state. For our childhood asthma incident cases
attributable to NO2 counts, we used state estimates which we developed in our previous
work reported in Khreis et al. [16]. For our cost numbers, we used the previously estimated
costs of a single childhood asthma case in each state as calculated from Nurmagambetov
et al. [21]. Our study’s results present a state level economic analysis that shows the cost of
a single case of asthma in each state and the total costs for all childhood asthma incident
cases attributable to NO2.
2.2. Estimation of Childhood Asthma Incident Cases Attributable to NO2
Our state level economic analysis focuses on estimating the state-specific economic
impacts of childhood asthma incident cases attributable to NO2. Our analysis focuses
on one traffic-related air pollutant, NO2. To calculate the economic cost, we used BoD
estimates of asthma at the state-level as reported in Khreis et al. [16], which is briefly
described next.
Khreis et al. [16] analyzed data for the 48 contiguous U.S. states and Washington D.C.
(D.C.) for 2010 at the census block level. The total population of children aged 0 to 18 in the
census data was 73,690,271, i.e., 24% of the total population. The number of children in
rural areas is 13,763,183 (19%), 6,994,464 (9%) in urban clusters, and 52,932,624 (72%) in
urbanized areas. The number of attributable childhood asthma cases were estimated at
the state level. This study used a concentration response function (CRF) to estimate the
association between the risk of childhood asthma onset and the exposure to NO2 of 1.05
(95% CI = 1.02–1.07) per 4 µg/m3 of NO2. The CRF was obtained from a meta-analysis of
20 studies examining the association between exposure to NO2 and the risk of developing
asthma among children from birth to 18 years of age [9]. Annual NO2 concentrations were
derived from a land-use regression (LUR) model that incorporates spatial and temporal
observed air pollutant data [29]. To estimate the state level incidence rate, this study
obtained childhood asthma data from the Behavioral Risk Factor Surveillance System
(BRFSS) and the Asthma Call-Back Survey (ACBS) from the years 2006 through 2010 [30–32].
In brief, Khreis et al. [16] determined the asthma status of children through the BRFSS and
the nested ACBS. To determine the asthma status of children, respondents to the BRFSS
were asked “Has a doctor, nurse, or other health professional ever said that the child has
asthma?” If the answer was “yes,” the respondent was designated as “ever asthma.” If the
answer was “no,” the respondent was designated as “never asthma.” Respondents with
children designated as “ever asthma” were requested to participate in the ACBS follow-up.
To determine the “incident status” of children, respondents to the ACBS were asked “How
old was [name of child] when a doctor or other health professional first said [he/she] had
asthma? How long ago was that?” If the answer to the latter part of this question was
“within the past 12 months,” the respondent was designated as an “incident asthma. Using
these data, in addition to sample sizes, sample weights and estimated population, Khreis
et al. [16] provided results of the state-specific incidence rates, different to other previous
work such as Alotaibi et al. [15]. These rates represent an average estimate from 2006 to
2010 for the states participating in the ACBS/BRFSS. Overall, there were 32 states that
had childhood asthma incidence rates and 41 states that had childhood asthma prevalence
rates. The remaining states that did not have an incidence rate were assigned the overall
aggregate asthma incidence rate as calculated from all available data [16].
To estimate the BoD of incident childhood asthma attributable to NO2 exposure,
the Khreis et al. [16] study followed the standard BoD assessment methods described in
Alotaibi et al. [15] and widely used in the literature. The total number of at-risk children
residing in a census block was estimated for each state. This was done by subtracting the
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total number of children within the census block multiplied by the state-specific prevalence
rate from the total number of children within the same census block. Khreis et al. [16]
estimated the number of childhood asthma incident cases within each census block by
multiplying the state-specific asthma incidence rate by the at-risk children in each census
block. Then, the relative risk was calculated for asthma onset due to the exposure difference
between the estimated exposure levels from the LUR model (NO2 concentration at the
centroid of each census block) and a hypothetical no exposure scenario (zero concentration
for NO2) at each census block [29]. The LUR model uses satellite data and Environmental
Protection Agency (EPA) air quality monitor readings of NO2 concentrations alongside
several covariates to estimate NO2 concentrations. The model also incorporates temporal
scaling by estimating average monthly monitor readings for 11 consecutive years. The
final model used has a relatively high predictive power at unmeasured locations, which
was tested using a hold-out cross-validation with good model performance (R2 = 0.82);
this is comparable with other continental scale NO2 LUR models [15,29]. The population-
attributable fraction (PAF) was then estimated at each census block. The attributable
number of asthma incident cases was estimated by multiplying the PAF with the total
number of asthma incident cases in each census block. The attributable number of asthma
incident cases for each census block was then summed across the state to obtain the total
state attributable number of asthma incident cases [16].
Khreis et al. [16] reported that South Dakota had the lowest mean NO2 concentration
(5.2 µg/m3), while D.C. had the highest (26.3 µg/m3). Across all states with available data,
the overall aggregate childhood asthma incidence rate for the years 2006–2010 was 11.6
per 1000 at-risk children. Montana had the lowest aggregate childhood asthma incidence
rate of 4.3 per 1000 at-risk children, followed by Louisiana’s incidence rate of 5.8 per 1000
at-risk children, while D.C. had the highest aggregate childhood asthma incidence rate of
17.7 per 1000 at-risk children, followed by Texas’s incidence rate of 16.6 per 1000 at-risk
children. States that did not have an incidence rate available were assigned the overall
aggregate asthma incidence rate of 11.6 per 1000 at-risk children.
2.3. Review of Sources for Costing across the U.S.
To complete an economic analysis of childhood asthma incident cases attributable to
NO2, we needed to estimate the cost of a single childhood asthma case in the U.S. To do
this, we needed to find data on the cost of each category of spending: hospitalizations,
office visits, prescription costs, emergency room costs, etc. We started our search by
researching public databases, such as IPUMS [census and survey data/ipums.org] and the
Medical Expenditure Panel Survey (MEPS), which provide raw data; however, due to a
lack of full public access and incomplete datasets, they were not viable options. Instead,
we conducted a database review and a literature review to determine the availability of
previously calculated estimations of cost across the different categories of spending. We
looked at public databases that had estimated costs from national surveys and presented
them for public use. Table 2 summarizes the database review and Table 3 summarizes the
literature review. Because this research study began with the intention to provide results
from both the national and the state level and in both years 2000 and 2010, both year ranges
are included in our data and literature review. However, through our research, our focus
was narrowed to the year 2010 and the state level incidence only rather than including
national estimates, to offer more spatial resolution in data analyses and presentation.
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HCUPnet 2000 3 3 3
HCUPnet 2010 3 3 3
HCUPnet 2000 3 3 3
HCUPnet 2010 3 3 3
HCUPnet 2010 3 3 3
AHRQ MEPS Summary Tables 2000 3 3 3
AHRQ MEPS Summary Tables 2010 3 3 3
Note: HCUPnet is an online query system based on data from the Healthcare Cost and Utilization Project (HCUP). The Agency for Healthcare
Research and Quality (AHRQ) Medical Expenditure Panel Survey (MEPS) summary tables provide frequently used summary estimates for
the U.S. civilian population on household medical utilization and expenditures, demographic and socio-economic characteristics, health
insurance coverage, access to care and experience with care, medical conditions, and prescribed medicine purchases.
Table 3. Published studies review.







Barrett et al. [33] 3 3 3
Barnett and Nurmagambetov. [34] 3 3 3 3
Wang et al. [35] 3 3 3
Nurmagambetov et al. [21] 3 3 3 3
Nurmagambetov et al. [23] 3 3 3 3
Sullivan et al. [36] 3 3 3
Karaca-Mandic et al. [37] 3 3 3
2.3.1. Database Review
Our database review looked at two sources from the Agency for Healthcare Research
and Quality (AHRQ): The Health Care Cost and Utilization Project (HCUP) and MEPS. We
reviewed each database for the type of direct or indirect costs they researched, how asthma
was defined, the year of the data, whether the database provided state estimates, and if
asthma costs for children under 18 were reported.
HCUPnet is a free, online query system based on data from the HCUP. The system pro-
vides health care statistics and information for hospital inpatient, emergency department,
and ambulatory settings, as well as county-level population-based health care data. We
looked for results in 2000 and 2010 at the national and state level, and the category of direct
costs (Inpatient or Emergency). HCUPnet did not provide indirect costs. These results are
summarized in Table 2 and with more detail in Table S1. A second source consulted was the
MEPS Household Component summary tables provided by AHRQ. The MEPS Household
Component summary tables provide frequently used summary estimates for the U.S. civil-
ian non-institutionalized population on household medical utilization and expenditures,
demographic and socio-economic characteristics, health insurance coverage, access to care
and experience with care, medical conditions, and prescribed medicine purchases. This
resource allows users to stratify by demographic or socio-economic characteristics and
plots are generated from selected data. It provides results for costs by category for the
entire population and a combined direct cost number for children under 18 at the national
level. This source internally defined asthma and combined the costs numbers with chronic
obstructive pulmonary disease when reporting the costs.
This database review allowed us to see results straight from national databases and
what the estimated costs were. The database review, along with the literature review
described below, was reviewed together to determine which source to extract cost numbers
from. The literature review is outlined in Section 2.3.2.
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Table 2 summarizes our findings from different databases and details the direct cost
estimates, the sample size of each database, the age makeup of the sample, how asthma
is defined in each source, and how costs are defined and calculated within each database.
Table S1 outlines this information in detail.
2.3.2. Review of the Published Studies for Costing in the U.S.
In addition to the database review described above, we conducted a literature review.
The literature review focused on finding published estimates for both direct and indirect
costs caused by childhood asthma in the U.S. Our review found seven relevant studies,
which are described in detail in Table S2 in the Supplementary Material, and briefly next.
Barrett et al. [33] reported the average cost per hospital stay for children aged 2 to 17 in
both 2000 and 2010 at the national level. This study used the same surveys from the HCUP
results (Table 2). Barnett and Nurmagambetov [34] estimated both the direct and indirect
costs of asthma for the U.S. population between 2002 and 2007 nationally. This study
estimated the cost for both the entire population and children aged 3 to 19. Wang et al. [35]
estimated both the direct and indirect cost per child aged 5 to 17 at the national level.
Nurmagambetov et al. [21] reported the direct and indirect costs for children aged 0 to 17
for each state. Nurmagambetov et al. [23] estimated the direct and indirect cost nationally
but did not break down the estimates for each event for children as they did for the rest
of the population. Sullivan et al. [36] estimated the national direct cost of asthma from
children aged 6 to 17. Karaca-Mandic et al. [37] estimated the out-of-pocket medication cost
for children under 5 and 5 to 17 with asthma. This literature review revealed the current
published cost estimates for childhood asthma in the U.S. Table 3 summarizes the findings
of our literature review and Table S2 in the Supplementary Materials outlines in detail the
direct and indirect costs of each study, the sample size, the age groups of the children, how
asthma was defined, and how cost was defined.
2.3.3. Choosing Our Cost Source
After conducting the two above reviews, we considered which sources provided
the best cost estimates for our purposes. We wanted to include both indirect and direct
costs for children under the age of 18 at both the national and state level. We anticipated
taking different cost information from different sources, but this was not feasible because
our source options studied different time frames, different age groups, defined asthma
differently, and looked at different categories of direct or indirect costs. Because of this, we
simplified our study to only focus on estimating the costs of childhood asthma in the U.S.
at the state level and in the year 2010 to correspond with the most recent Khreis et al. [16]
study, which offers more spatial resolution in data analyses and presentation. Our selected
cost source after reviewing our options above was the Nurmagambetov et al. [21] study.
2.4. Estimation of Costs per Childhood Asthma Case in the U.S.
We used Nurmagambetov et al. [21] as our cost source, as it estimates both the direct
and indirect costs for children in the U.S., using the most recent available data at the
time of their study (2008–2012 data from MEPS). The study also used other data sources:
the 2004 National Nursing Home Survey, National Health Accounts, 2000 and 2010 U.S.
Census Bureau, 2012 Current Population Survey, Kaiser Family Foundation, 2012 Medicare
Beneficiaries data, 2011 Medicaid Statistical Information Statistics, 2014 Bureau of Labor
Statistics (BLS) data, and the 2015 Congressional Budget Office Long-Term Budget Outlook.
To define asthma, Nurmagambetov et al. [21] used the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Code 493. For direct costs, the
study describes the direct costs as the summation of all payments when treating asthma.
This includes emergency room visits, office-based medical visits, outpatient hospital visits,
and prescription medications by the payer. The study defines indirect costs as the total cost
of missed school and workdays.
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In order to estimate the per capita asthma-attributable medical costs, Nurmagambetov
et al. [21] used the 2008–2012 MEPS dataset. This dataset describes medical costs as payer’s
expenses and represents the total annual sum that a payer spent on an individual’s medical
care. The study presented costs from three payer systems: Medicaid, Medicare, and private
insurance. Direct costs were estimated for all payers as the total of all medical expenditures
spent by all payers, including out-of-pocket payments.
A two-part model was used to approximate annual medical expenditures attributable
to asthma: a logistical regression and a generalized linear model was used by Nurmagam-
betov et al. [21]. The first part was a logistic regression which predicts the probability that a
person acquired any medical costs. The second part was a linear model with a log link and
a gamma distribution. This part estimated the annual medical costs for those with positive
expenditure. This model generated the incremental cost of asthma. The incremental cost of
asthma is the difference between the predicted annual medical costs of the person with
asthma and the predicted annual medical costs of the same person if the person does not
have asthma. This model separated asthma’s impact on medical costs while controlling for
other factors that can affect health care costs.
To find state level direct costs, previously generated state level cost adjustments
from the restricted-access 2003 MEPS dataset was used [21]. Previously generated state-
specific cost adjustments for the states were applied. The state level adjustment factors
from the 2003 MEPS dataset were multiplied with the 2012 per person cost estimates
from the national model. For each state, Nurmagambetov et al. [21] calculated the total
medical direct costs by multiplying the average per person asthma-attributable medical
expenditures by the number of people with asthma and combining the costs across age
and sex categories within each state and payer category.
In the same study, absenteeism or indirect costs are represented by the cost of missed
school or workdays. Nurmagambetov et al. [21] presumed that when a child missed school
due to asthma, one of the parents (if both were employed) stayed home with the child,
which meant missing a day work. The daily salary of that parent is the value of one day
of absenteeism [38,39]. Nurmagambetov et al. [21] used the 2008–2012 MEPS dataset to
estimate the number of annual workdays lost per capita (for adults) and schooldays (for
children) that were caused by asthma. To predict the annual workdays missed among
working adults, a negative binomial model where the dependent variable was the an-
nual workdays and the independent variables were identical to those in the medical cost
regressions was used.
The study used a similar approach to estimate schooldays missed among children.
For each state, Nurmagambetov et al. [21] calculated the total number of workdays missed
by multiplying the age- and sex-specific number of per capita workdays missed by the
corresponding age- and sex-specific number of employed adults with children with asthma.
They estimated the value of missed workdays using average daily earnings (including
fringe benefits) from the 2014 BLS data.
Nurmagambetov et al. [21] reported the per child (under 18) direct indirect cost in
each state. The study did not provide the per person indirect costs, but rather the total in
each state. Thus, we took the total cost reported and divided it by the number of children
with asthma and employed parents as reported by Nurmagambetov et al. [21]. The divided
cost gave us the per child (under 18) indirect cost in each state.
2.5. Cost Calculation
We calculated the total childhood asthma incident case’s cost attributable to NO2
at the state level by adding the total direct costs with the total indirect costs to yield the
total cost of a childhood incident case attributable to NO2 in each state. We used the
per person direct cost per state estimated by Nurmagambetov et al. [21] and multiplied
it by the number of childhood asthma incident cases attributable to NO2 in each state
estimated by Khreis et al. [16]. That calculation gave us the total direct medical cost in the
U.S. for each state. We then used the total indirect costs estimated by Nurmagambetov
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et al. [21], which we divided by the total number of children with working parents as
explained above. This gave us the per person indirect costs for childhood asthma. We then
multiplied the childhood asthma incident cases attributable to NO2 from Khreis et al. [16]
with both the direct and indirect costs separately to get the total cost of the direct and
indirect expenditures in each state. We then added the direct and indirect costs for each




The state with the highest annual cost burden was California with about $24,501,859.84
(95% Confidence Interval (CI): $10,020,182.62–$38,982,261.250), and it had the highest
number of NO2-attributable childhood asthma incident cases of 19,205 (95% CI: 7854—
30,555). The state with the lowest annual cost was Montana with $88,880.12 (95% CI:
$33,491.06–$144,269.18), and it had the lowest number of NO2-attributable childhood
asthma incident cases of 69 (95% CI: 26–112). Table 3 reports the total annual cost of
NO2-attributable childhood asthma incident cases in the U.S. at $178,900,138.989 (95% CI:
$101,019,728.20–$256,980,126.65). This represents 19.8% of the cost of all asthma cases in
the U.S., calculated by using the total pediatric asthma cases in each state from Khreis
et al. [16] and the per child cost of asthma in each state from Nurmagambetov et al. [21].
Our calculation steps are outlined in Table S3.
3.2. Direct and Indirect Costs Breakdown
The state with the highest annual direct cost burden was California with $16,593,120
(95% CI: $6,785,856–$26,399,520), and the state with the lowest direct cost burden was
Montana with $68,586 (95% CI: $25,844–$111,328). The total annual direct cost burden
in the U.S. was $129,950,707 (95% CI: $73,785,005–$186,264,165), which represents 72.6%
from the total cost of NO2-attributable childhood asthma incident cases. The state with
the highest annual indirect cost burden was also California with $7,908,739.84 (95% CI:
$3,234,326.62–$12,582,741.25), and the state with the lowest annual indirect cost burden
was also Montana with $20,294.12 (95% CI: $7647.06–$32,941.18). These trends mirrored
trends in the number of NO2-attributable childhood asthma incident cases in California (the
highest) and Montana (the lowest), while trends in the per child direct and indirect costs
differed (see the supplementary excel file, which shows the full calculations). The total an-
nual indirect cost of NO2-attributable childhood asthma incident cases was $48,949,431.98
(95% CI: $27,234,723.20–$70,715,961.65), which represents 27.4% of the total annual cost of
NO2-attributable childhood asthma incident cases (Table 4).
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Total Indirect Cost of Childhood Asthma
Incident Cases Attributable to NO2
(95% CI)
Total Indirect and Direct Costs of Childhood
Asthma Incident Cases Attributable to NO2
(95% CI)
Alabama 1330 (1330–1330) $983 $1,307,390 ($1,307,390–$1,307,390) $309.02 $410,998.08 ($410,998.08–$410,998.08) $1,718,388.08 ($1,718,388.08–$1,718,388.08)
Arizona 4623 (0–9273) $833 $3,850,959 ($0–$7,724,409) $337.35 $1,559,566.27 ($0.00–$3,128,240.96) $5,410,525.27 ($0.00–$10,852,649.96)
Arkansas 945 (945–945) $860 $812,700 ($812,700–$812,700) $287.88 $272,045.45 ($272,045.45–$272,045.45) $1,084,745.45 ($1,084,745.45–$1,084,745.45)
California 19205 (7854–30,555) $864 $16,593,120 ($6,785,856–$26,399,520) $411.81 $7,908,739.84 ($3,234,326.62–$12,582,741.25) $24,501,859.84 ($10,020,182.62–$38,982,261.25)
Colorado 3292 (3291–3292) $1076 $3,542,192 ($3,541,116–$3,542,192) $383.60 $1,262,804.23 ($1,262,420.63–$1,262,804.23) $4,804,996.23 ($4,803,536.63–$4,804,996.23)
Connecticut 1502 (818–2186) $1084 $1,628,168 ($886,712–$2,369,624) $416.33 $625,334.66 ($340,561.75–$910,107.57) $2,253,502.66 ($1,227,273.75–$3,279,731.57)
Delaware 386 (26–746) $1032 $398,352 ($26,832–$769,872) $378.95 $146,273.68 ($9,852.63–$282,694.74) $544,625.68 ($36,684.63–$1,052,566.74)
D.C. 313 (313–314) $1023 $320,199 ($320,199–$321,222) $612.24 $191,632.65 ($191,632.65–$192,244.90) $511,831.65 ($511,831.65–$513,466.90)
Florida 5863 (5862–5864) $976 $5,722,288 ($5,721,312–$5,723,264) $319.33 $1,872,245.02 ($1,871,925.69–$1,872,564.35) $7,594,533.02 ($7,593,237.69–$7,595,828.35)
Georgia 2772 (1353–4190) $935 $2,591,820 ($1,265,055–$3,917,650) $340.54 $943,965.43 ($460,745.03–$1,426,845.29) $3,535,785.43 ($1,725,800.03–$5,344,495.29)
Idaho 571 (571–571) $993 $567,003 (567,003–$567,003) $305.34 $174,351.15 ($174,351.15–$174,351.15) $741,354.15 ($741,354.15–$741,354.15)
Illinois 4509 (186–8832) $1013 $4,567,617 ($188,418–$8,946,816) $375.35 $1,692,453.78 ($69,815.13–$3,315,092.44) $6,260,070.78 ($258,233.13–$12,261,908.44)
Indiana 3852 (2450–5254) $1030 $3,967,560 ($2,523,500–$5,411,620) $314.44 $1,211,222.67 ($770,377.87–$1,652,067.48) $5,178,782.67 ($3,293,877.87–$7,063,687.48)
Iowa 519 (260–777) $984 $510,696 ($255,840–$764,568) $309.52 $160,642.86 ($80,476.19–$240,500.00) $671,338.86 ($336,316.19–$1,005,068.00)
Kansas 787 (533–1040) $973 $765,751 ($518,609–$1,011,920) $319.40 $251,370.15 ($170,241.79–$332,179.10) $1,017,121.15 ($688,850.79–$1,344,099.10)
Kentucky 1532 (1532–1532) $984 $1,507,488 ($1,507,488–$1,507,488) $302.97 $464,144.07 ($464,144.07–$464,144.07) $1,971,632.07 ($1,971,632.07–$1,971,632.07)
Louisiana 653 (0–1449) $895 $584,435 ($0–$1,296,855) $303.68 $198,299.81 ($0.00–$440,025.15) $782,734.81 ($0.00–$1,736,880.15)
Maine 173 (69–277) $933 $161,409 ($64,377–$258,441) $321.43 $55,607.14 ($22,178.57–$89,035.71) $217,016.14 ($86,555.57–$347,476.71)
Maryland 2454 (1501–3406) $929 $2,279,766 ($1,394,429–$3,164,174) $409.97 $1,006,061.09 ($615,361.74–$1,396,350.48) $3,285,827.09 ($2,009,790.74–$4,560,524.48)
Massachusetts 2705 (2705–2706) $997 $2,696,885 ($2,696,885–$2,697,882) $434.88 $1,176,353.34 ($1,176,353.34–$1,176,788.22) $3,873,238.34 ($3,873,238.34–$3,874,670.22)
Michigan 4056 (2554–2558) $1121 $4,546,776 ($2,863,034–$6,230,518) $340.55 $1,381,253.06 ($869,753.53–$1,892,752.59) $5,928,029.06 ($3,732,787.53–$8,123,270.59)
Minnesota 2045 (2045–2046) $999 $2,042,955 ($2,042,955–$2,043,954) $370.99 $758,684.65 ($758,684.65–$759,055.65) $2,801,639.65 ($2,801,639.65–$2,803,009.65)
Mississippi 929 (275–1583) $860 $798,940 ($236,500–$1,361,380) $274.57 $255,072.25 ($75,505.78–$434,638.73) $1,054,012.25 ($312,005.78–$1,796,018.73)
Missouri 1898 (443–3353) $907 $1,721,486 ($401,801–$3,041,171) $326.19 $619,102.60 ($144,500.77–$1,093,704.44) $2,340,588.60 ($546,301.77–$4,134,875.44)
Montana 69 (26–112) $994 $68,586 ($25,844–$111,328) $294.12 $20,294.12 ($7,647.06–$32,941.18) $88,880.12 ($33,491.06–$144,269.18)
Nebraska 494 (298–690) $972 $480,168 ($289,656–$670,680) $313.08 $154,663.55 ($93,299.07–$216,028.04) $634,831.55 ($382,955.07–$886,708.04)
Nevada 1377 (1377–1377) $994 $1,368,738 ($1,368,738–$1,368,738) $330.05 $454,477.83 ($454,477.83–$454,477.83) $1,823,215.83 ($1,823,215.83–$1,823,215.83)
New Hampshire 329 (163–496) $935 $307,615 ($152,405–$463,760) $352.60 $116,005.78 ($57,473.99–$174,890.17) $423,620.78 ($209,878.99–$638,650.17)
New Jersey 4155 (2321–5989) $1034 $4,296,270 ($2,399,914–$6,192,626) $415.17 $1,725,023.46 ($963,605.16–$2,486,441.75) $6,021,293.46 ($3,363,519.16–$8,679,067.75)
New Mexico 471 (215–726) $993 $467,703 ($213,495–$720,918) $318.47 $150,000.00 ($68,471.34–$231,210.19) $617,703.00 ($281,966.34–$952,128.19)
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Total Indirect and Direct Costs of Childhood
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New York 13,504 (7076–10,932) $1003 $13,544,512 ($7,097,228–$19,991,796) $424.25 $5,729,122.39 ($3,002,019.40–$8,456,225.37) $19,273,634.39 ($10,099,247.40–$28,448,021.37)
North Carolina 3390 (3390–3391) $976 $3,308,640 ($3,308,640–$3,309,616) $329.26 $1,116,180.62 ($1,116,180.62–$1,116,509.88) $4,424,820.62 ($4,424,820.62–$4,426,125.88)
North Dakota 137 (137–137) $971 $133,027 ($133,027–$133,027) $323.94 $44,380.28 ($44,380.28–$44,380.28) $177,407.28 ($177,407.28–$177,407.28)
Ohio 6165 (3011–9319) $927 $5,714,955 ($2,791,197–$8,638,713) $334.94 $2,064,903.61 ($1,008,503.61–$3,121,303.61) $7,779,858.61 ($3,799,700.61–$11,760,016.61)
Oklahoma 1154 (620–1687) $944 $1,089,376 ($585,280–$1,592,528) $308.76 $356,304.15 ($191,428.57–$520,870.97) $1,445,680.15 ($776,708.57–$2,113,398.97)
Oregon 1180 (282–2078) $997 $1,176,460 ($281,154–$2,071,766) $359.85 $424,621.21 ($101,477.27–$747,765.15) $1,601,081.21 ($382,631.27–$2,819,531.15)
Pennsylvania 6305 (1764–10,846) $980 $6,178,900 ($1,728,720–$10,629,080) $345.89 $2,180,814.02 ($610,143.68–$3,751,484.36) $8,359,714.02 ($2,338,863.68–$14,380,564.36)
Rhode Island 422 (130–713) $933 $393,726 ($121,290–$665,229) $372.26 $157,094.89 ($48,394.16–$265,423.36) $550,820.89 ($169,684.16–$930,652.36)
South Carolina 1371 (1371–1372) $961 $1,317,531 ($1,317,531–$1,318,492) $300.00 $411,300.00 ($411,300.00–$411,600.00) $1,728,831.00 ($1,728,831.00–$1,730,092.00)
South Dakota 176 (176–176) $972 $171,072 ($171,072–$171,072) $287.23 $50,553.19 ($50,553.19–$50,553.19) $221,625.19 ($221,625.19–$221,625.19)
Tennessee 2667 (2667–2667) $1096 $2,923,032 ($2,923,032–$2,923,032) $308.36 $822,389.05 ($822,389.05–$822,389.05) $3,745,421.05 ($3,745,421.05–$3,745,421.05)
Texas 14,316 (7776–20,856) $961 $13,757,676 ($7,472,736–$20,042,616) $345.38 $4,944,481.93 ($2,685,686.75–$7,203,277.11) $18,702,157.93 ($10,158,422.75–$27,245,893.11)
Utah 1672 (1048–2295) $991 $1,656,952 ($1,038,568–$2,274,345) $325.93 $544,948.15 ($341,570.37–$748,000.00) $2,201,900.15 ($1,380,138.37–$3,022,345.00)
Vermont 126 (81–1710 $934 $117,684 ($75,654–$159,714) $333.33 $42,000.00 ($27,000.00–$57,000.00) $159,684.00 ($102,654.00–$216,714.00)
Virginia 3200 (3200–3201) $1011 $3,235,200 ($3,235,200–$3,236,211) $387.21 $1,239,069.77 ($1,239,069.77–$1,239,456.98) $4,474,269.77 ($4,474,269.77–$4,475,667.98)
Washington 1703 (950–2456) $995 $1,694,485 ($945,250–$2,443,720) $404.12 $688,222.68 ($383,917.53–$992,527.84) $2,382,707.68 ($1,329,167.53–$3,436,247.84)
West Virginia 578 (42–1114) $1033 $597,074 ($43,386–$1,150,762) $286.52 $165,606.74 ($12,033.71–$319,179.78) $762,680.74($55,419.71–$1,469,941.78)
Wisconsin 2154 (1–4307) $1081 $2,328,474 ($1,081–$4,655,867) $325.73 $701,628.66 ($325.73–$1,402,931.60) $3,030,102.66($1,406.73–$6,058,798.60)
Wyoming 138 (138–138) $992 $136,896 ($136,896–$136,896) $341.46 $47,121.95 ($47,121.95–$47,121.95) $184,017.95($184,017.95–$184,017.95)
Total: $129,950,707 ($73,785,005–$186,264,165) $48,949,431.98 ($27,234,723.20–$70,715,961.65) $178,900,138.989 ($101,019,728.20–$256,980,126.65)
Note: All costs are in 2014 dollars.
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4. Discussion
4.1. Summary and Comparison to Previous Work
In this article, we monetized childhood asthma incident cases specifically attributable
to NO2 in the U.S. at the state level. We calculated both the direct and indirect costs,
which were then summed to estimate the total cost of childhood asthma incident cases
attributable to NO2 in each state. We conducted this analysis building on previously pub-
lished estimates in Khreis et al. [16] and Nurmagambetov et al. [21] of both the attributable
pediatric asthma incident cases due to NO2 and asthma costs, after conducting a database
and literature search for sources on the cost of childhood asthma in the U.S.
Our estimation shows the estimated cost burden of NO2 to be $178,900,138.989 (95% CI:
$101,019,728.20–$256,980,126.65). This total represents 19.8% of all pediatric asthma costs
in the U.S. It is important to denote that this economic impact only represents NO2, which
we selected as it is a more specific pollutant to the TRAP mixture and does not represent
the cost for other traffic-related related pollutants, which may be higher or lower [15,17].
Our literature review, shown in Table 1, only found one national published study
that estimated the cost of pediatric asthma associated with air pollution. However, that
study was restricted only to estimating the relation between sub-chronic exposures to air
pollutants and hospitalization costs and did not expand to other categories of direct or
indirect costs [27]. The methodology of Roy et al. [27] is also very different than our study,
as we built on a previously published BoD assessment and published direct and indirect
asthma costs by state. Our study fills a gap in the literature with an overarching assessment
of the full economic impacts of childhood asthma incident cases attributable to NO2, at the
U.S. state level.
Previous studies which estimated the cost of asthma associated with or attributable
to air pollution were either conducted in small communities or cities, different countries,
or focused on only a few cost variables (e.g., hospitalization costs only) (Table 1). Guo
and Chen. [26] studied the short-term effect of outdoor air pollution on asthma-related
patient visits and their economic costs and calculated the costs of patient visits by each
pollutant, i.e., SO2, O3, CO, PM2.5, PM10, and NO2, in Shanghai, China. The study found
that the total loss was 197 million U.S. dollars per year [26]. Brandt et al. [25] estimated the
cost of childhood asthma cases attributable to residential near roadway pollution (NRP) in
Los Angeles County for regional O3, and NO2 in 2007. The study found that the cost of
air pollution-related asthma in Los Angeles County in 2007 was $441 million for O3 and
$202 million for NO2 in 2010. These estimates are significantly higher compared to our
estimates and are not directly comparable. This may be due to a few reasons. The study
by Brandt et al. [25] looked at both the direct and indirect costs of asthma attributable to
air pollution, and the direct and indirect costs of an asthma case exacerbation, regardless
of the immediate cause of exacerbation. They included causes which are not related to
air pollution, and the willingness to pay (WTP) for a household beyond the household’s
current expenditures. In addition, Brandt et al. [25] had a higher number of childhood
asthma cases attributable to NRP at 27,100 (95% CI, 4900–51,200), making their total cost
for asthma cases attributable to air pollution higher compared to our study. This study
used the asthma prevalence estimated from a previous study, i.e., Perez et al. [40]. This
study also estimated asthma cases attributable to near-roadway and regional air pollution
in Los Angeles County using a CRF from the Children’s Health Study that is different from
the CRF underlying our work. For their cost calculations, they estimated the direct cost of
goods and services and the indirect cost of caregivers’ lost wages. For the direct costs of
health care, they used the amount charged rather than the amount paid because amounts
charged are not confounded by insurance status. This put their total costs to be $3000 per
asthma case and $1500 per a single episode of bronchitis. As such, our estimates are not
directly comparable due to the many methodological differences, as outlined above.
Brandt et al. [28] estimated the cost of childhood asthma cases attributable to TRAP
in two Californian cities using proximity to traffic to indicate the TRAP exposure and
levels of NO2 and O3 to estimate the cost of air pollution attributable exacerbations of
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asthma, following methods similar to Brandt et al. [25]. The authors found that the annual
costs of TRAP-attributable cases were U.S. $2,808,300 in Riverside and U.S. $6,120,000 in
Long Beach. This study estimated case counts using their previous study, Perez et al. [41],
which estimated childhood asthma-related illnesses by deriving population-attributable
risk fractions in a BoD assessment framework, including scenario analyses. Compared to
our study, Brandt et al. [28] also has higher attributable asthma cases and higher per person
asthma costs, although these are not directly comparable, as they pertain to only two
communities in California, rather than the whole state. The authors included bronchitis
episodes and exacerbations of other-cause asthma cases from air pollutants. Their indirect
costs were 3× higher when compared to our study for the state of California specifically, but
as highlighted above, there are many methodological differences that hinder comparability
and highlight that the total cost may be much higher if the exacerbations of asthma cases,
both TRAP and non-TRAP induced, were included in our analyses. However, our scope
was different and only focused on estimating the cost of those cases specifically induced
by TRAP. While our study fills an important research gap and presents a comprehensive
estimate of the cost of asthma in each state and both direct and indirect costs, when
compared to current published estimates, our costs may be underestimated.
Another study, Roy et al. [27], examined the association between sub-chronic exposure
(in between acute and chronic) to six outdoor air pollutants, PM2.5, PM10, O3, NO2, SO2,
CO, with both hospital costs and length of stay of pediatric asthma hospitalization in
the U.S. The study found that a 1-unit (µg/m3) increase in monthly PM2.5 led to a $123
increase in charges (95% CI: $40–249) and a $47 increase in costs (95% CI: $15–93). This
study only looked at two cost factors, hospital costs and length of stay of pediatric asthma
hospitalization in the U.S., while our study looked at both direct and indirect costs.
Our study, using the estimates from Nurmagambetov et al. [21], put a total cost of a
pediatric asthma case on average to be $1196 in the U.S. Our study’s direct costs were the
medical cost to a payer. A payer’s medical costs is the sum of all payments for emergency
room visits, office-based medical provider visits, outpatient hospital visits, and prescription
medications. As they used the MEPS dataset, the medical costs are payer’s expenses and
represent the total annual amount that a payer spent on their medical care and prescription
medications.
4.2. Strengths and Limitations
Our results are all estimates based on the best available and peer reviewed literature,
but they are still estimates with many limitations, as explained below. We provide a 95%
CI around each state’s central estimate to provide a range of uncertainty. The results of
our estimation are subject to several limitations. Any limitations from our two source
studies [16,21] will carry over to this study. Khreis et al. [16] selected NO2 as the exposure
of interest (thus so did we), as it has been the most commonly used pollutant in previous
BoD analyses and a larger body of studies supports its use as an appropriate CRF [9].
NO2 is also a relatively good marker for TRAP, compared to PM2.5 and PM10, which are
the two other pollutants for which we have childhood asthma BoD estimates [15]. It can
be argued, however, that NO2 is not the putative agent but rather serves as a surrogate
pollutant for the mixture of fresh traffic exhaust and its variation in urban areas. There
is stronger and more toxicological evidence that links particulate matter with incident
asthma and emerging evidence to suggest that certain chemical components of particulate
matter, such as black carbon, ammonium, and nitrates, may be more relevant in the
onset of asthma [13,42]. However, this issue was less relevant in the original analysis by
Khreis et al. [16], as the only aim of that study was to establish the potential impact of
using different baseline asthma incidence rates on the final burden of disease estimates.
Possible interactions between pollutants were not considered, as there are very limited
epidemiological data to investigate this, and as such, we do not comment on this matter
further. Khreis et al. [16] also had limitations in the datasets they used to estimate the
state-specific asthma incidence rates, and these limitations are relevant here. The total
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childhood samples included for the period 2006–2010 were 293,464 samples from the BRFSS
and 16,156 samples from the ACBS. These samples were, however, weighted to represent
the total number of children within each state, with similar characteristics (e.g., age, sex,
and race). In other words, weights were used to convert samples to population estimates
of children. A larger sample size in these surveys may have more accurately represented
the U.S. childhood population of approximately 73 million in 2010, which we included in
our analysis, but this is not established. Furthermore, NO2 exposures were estimated for
the year 2010, whereas the estimation of the asthma incidence rates utilized data from 2006
to 2010. The reason why Khreis et al. [16] included earlier years of data in the estimation
of their asthma incidence rates was because many states did not have survey results for
the year 2010, and relying on 2010 data only would mean that they would have to exclude
those states from the analysis, and therefore, not cover the whole of the U.S. Importantly,
because the estimation of asthma incidence rates was carried out at a finer spatial resolution
in their study (at the state versus the national level), the sample sizes available for their
estimation were reduced, and using the aggregate data for the years 2006 to 2010 increases
the sample sizes and, therefore, the confidence in the incidence rate estimates. Ideally,
enough data would have been available to allow a complete and robust calculation of
asthma incidence rates for the year 2010 specifically, but as the aim of their study was
to establish the potential impact of using different incidence rates only, this aim was not
compromised using aggregate survey data over the years 2006 to 2010. Khreis et al. [16]
relied on state-specific pediatric asthma incidence rates in their analysis, but sub-state
variations most likely exist, including between urban and rural populations, and across
different races, sexes, ages, and socioeconomic status [16]. Unfortunately, this information
was not readily available, limiting the ability to estimate subpopulation specific asthma
incidence rates within each state; however, this is also less relevant to the aim of this study,
which is to conduct an economic analysis showing the total cost of childhood asthma
incident cases attributable to NO2 in each state.
The LUR models used by Khreis et al. [16] estimated concentrations at the centroid of
census blocks, which could be a farther point from roadways since census blocks are usually
classified by roadways. They were unable to verify how this would affect the direction
of exposure or exposure misclassification since calculating the average concentration at a
finer scale within census blocks was not feasible due to the large computational intensity
needed to predict values across the whole of the U.S. [15,16,29].
The MEPS dataset was used as the primary source of data by Nurmagambetov
et al. [21]. This dataset may underestimate the total medical costs, because first, it does not
capture all medical care consumption and costs. Some of the use that was not captured may
have included non-durable goods, such as over-the counter medications or prescription
drugs, and health services administered in non-medical settings, such as health screenings
delivered in non-health establishments such as the workplace and school. Second, a com-
parison of the MEPS data with other medical use data revealed that MEPS respondents
tend to underreport medical events, which can lead to an underestimate of use and thus
costs [43–45].
The estimates from Nurmagambetov et al. [21] of the per person costs are based on a
national regression model. Even though they applied state level adjustment factors from
the 2003 restricted used MEPS data, their results are still based on an assumption that the
geographical difference in medical costs across the states has remained the same since 2003.
This is relevant as we were not able to have the most up to date and accurate medical costs
according to each state for the year of analysis.
Nurmagambetov et al. [21] also cautioned against a direct comparison of the costs
across states for two reasons. First, the costs were derived from data across different
levels of geographic levels. Second, survey weights from MEPS were not intended to
be representative of state populations. This is pertinent as using MEPS may not have
accurately characterized state populations and costs. Additionally, while the authors
provided absenteeism cost of asthma as an important measure of indirect costs to the
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society, there were additional indirect cost factor that were not considered. These include
estimates of productivity losses through caregiving to adults with asthma, household
productivity losses, reduced productivity while at work, drops in the quality of life, and
premature mortality. This may have caused a lower estimate of indirect costs when
comparing with studies such as Brandt et al. [25], where the value of the caregiver’s time
spent traveling, waiting, and receiving care were included in addition to missed workdays.
In addition to the above limitations from our two source studies, our study has other
limitations.
First, our two source studies, Nurmagambetov et al. [21] and Khreis et al. [16], defined
asthma differently. Nurmagambetov et al. [21] defined childhood asthma as it was defined
in MEPS. In MEPS, self-reported conditions are recorded by professional coders using
ICD-9-CM codes and are then grouped into clinical classification system (CCS) codes.
Nurmagambetov et al. [21] defined asthma using ICD-9-CM code 493 and CCS code
128 and used only cases associated with reported medical use. Specifically, a MEPS
respondent with asthma ICD-9-CM or CCS codes was only considered to have a case of
medically treated asthma if they had at least one of the following medical procedures: a
hospitalization, an emergency department visit, an office-based medical provider visit,
an outpatient hospital visit, or the reported use of prescription drugs. Nurmagambetov
et al. [21] categorized people with no asthma-related medical events during that year as
not having medically treated asthma, regardless of if the person had a previous diagnosis
of asthma. This exclusion could underestimate the future cost of asthma for those with the
condition, as it does not account for possible future relapses.
On the other hand, Khreis et al. [16] determined the asthma status of children through
the BRFSS and the nested ACBS. To determine the asthma status of children, respondents
to the BRFSS were asked “Has a doctor, nurse, or other health professional ever said
that the child has asthma?” If the answer was “yes,” the respondent was designated as
“ever asthma.” If the answer was “no,” the respondent was designated as “never asthma.”
Respondents with children designated as “ever asthma” were requested to participate in
the ACBS follow-up. To determine the “incident status” of children, respondents to the
ACBS were asked “How old was [name of child] when a doctor or other health professional
first said [he/she] had asthma? How long ago was that?” If the answer to the latter part
of this question was “within the past 12 months,” the respondent was designated as an
“incident asthma.” Both studies, since they used different asthma definitions, could be
capturing different asthma populations and different asthma severities.
Another limitation in this study is presenting the costs as a total for all the U.S. by
adding all the states’ total costs together. When looking at these numbers, it is important to
note that Nurmagambetov et al. [21] do not total their cost numbers. As mentioned above,
they caution against a direct comparison of the results across states.
Our study’s strengths include being one of the first to provide a comprehensive
assessment of the economic cost of childhood asthma cases attributable to NO2 across
the contiguous U.S. Furthermore, throughout the research process, we discovered a lack
of research on the burden of pediatric asthma costs. Some comprehensive studies did
report the childhood cost of asthma but did not provide a breakdown of the burden by
direct and indirect costs [23]. Moreover, no study has used this information yet to estimate
the economic burden of childhood asthma attributable to TRAP. This study fills this gap,
although our estimates are subject to some limitations (outlined above) and may represent
an underestimation of the true cost of the disease, as already discussed.
4.3. Policy Implications
Air pollution continues to be a global threat to human health, contributing to a
substantial but modifiable BoD and premature mortality. About 90% of people breathe
air that does not comply with the World Health Organization Air Quality Guidelines [46];
guidelines which are still too high to protect human health [16]. According to a 2015
global BoD Study, exposure to PM2.5 is the fifth leading risk factor for death worldwide,
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accounting for 4.2 million deaths and 103.1 million disability-adjusted life-years in 2015 [47].
Air pollution also has several effects on different health issues including, but not limited to,
cardiovascular disease, lung cancer, diabetes, adverse birth outcomes, congenital anomalies,
pregnancy-induced hypertensive disorders and preeclampsia, and adverse respiratory
outcomes beyond asthma, especially in susceptible populations such as children and the
elderly. The list of associated health effects continues to grow and now includes health
effects which were not associated with TRAP a decade or so ago, such as autism and child
behavioral problems, cognitive decline, dementia and Alzheimer’s disease, obesity, and
an increased number of osteoporosis-related fracture hospital visits and decreased bone
density [48]. Adverse health effects associated with TRAP continue to emerge at a very
rapid pace [49], and the body of evidence has been strengthened substantially to demand
urgent action [48,50–52].
The economic burden of air pollution is also high. Health-related costs from the
effects of O3 air pollution exceeding national standards have been estimated at $6.5 billion
nationwide (in 2008 U.S. dollars), based on a U.S. assessment of health impacts from
O3 levels during 2000–2002 [53]. In the UK, the associated annual health costs of health
outcomes resulting from exposure to air pollution have been estimated at between £22.6
billion and £71.3 billion [54]. Data generated by the Centre for Research on Energy and
Clean Air and Greenpeace model suggests that an estimated global annual cost of U.S. $2.9
trillion (central estimate), equivalent to 3.3% of global Gross Domestic Product (GDP) or
U.S. $8 billion per day, is attributed to air pollution from fossil fuels. Costs of U.S. $350
billion and U.S. $380 billion are estimated to be attributed to NO2 and O3 air pollution
from fossil fuels, respectively, each equivalent to 0.4% of the global GDP [55].
While costing exercises have been mainly conducted for mortality impacts in the past,
assessing the cost of morbidity endpoints is also important and encouraged, especially
when the disease in question is chronic and carries over the life course of individuals.
One of these endpoints is childhood asthma. We think it is important to understand the
cost of TRAP-related childhood asthma incidence due to its economic implications and
the fact that this disease is chronic. When chronic bronchitis (a form of COPD) had been
included in EPA risk assessments in the past, this component of the health impact monetary
valuation was the largest morbidity effect, exceeded only by mortality in dollar valuation,
showing the importance of including the cost of morbidity. This high cost is because, a
person getting a chronic disease is a long-term adverse effect on their quality of life and,
therefore, there could be a high willingness to pay-to-avoid dollar value associated with
new onset of chronic diseases.
If we reduce TRAP, we can reduce childhood asthma cases, acute and chronic, and
reduce the financial burden of it. With a reduced financial burden, there would be increased
Medicare and Medicaid budgets in states that could be used for addressing other health
issues. Estimates that assume no change in regulatory controls or population characteristics
have ranged from 1000 to 4300 additional premature deaths nationally per year by 2050
from combined O3 and particle health effects according to the Centers of Disease Con-
trol [54]. As the first study to monetize the cost of childhood asthma attributable to NO2 in
the U.S., we urge for future research on the topic to reaffirm our findings and put them
in perspective, in addition to starting to investigate the costs of other chronic endpoints
which have been convincingly associated with air pollution.
These estimates should be factored into the regulatory framework for air quality
standards and in cost-benefits analyses of projects with an air pollution impact, including
transportation infrastructure and planning projects. Policy makers could also respond
in a few other ways, first by increasing funding for studies related to air pollution and
health research, especially the monetization of these impacts, and second, by focusing on
strategies on how to mitigate TRAP and human exposures.
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5. Conclusions
This study conducted the first state level economic analyses on TRAP-attributable
childhood asthma cases in the U.S. to help provide information on the high costs of TRAP-
attributable health impacts. The results of the analysis suggest that the total burden in
the states to be $178,900,138.989 (95% CI: $101,019,728.20–$256,980,126.65), which is likely
underestimated, as we showed in our discussion. Our analysis suggests $178,900,138.989 is
19.8% of all asthma costs. This demonstrates that TRAP, represented by NO2 in this work,
has large economic and health impacts. Future estimates need to capture the most accurate
pediatric asthma case count across the U.S., in addition to the most accurate cost of treating
asthma, as costs can vary, and any additional health problems that may be exacerbated due
to asthma, as well as their costs, to get a full and more accurate picture of the cost burden
of pediatric asthma.
The present-day cost of asthma estimates based on nationally recognized databases
and thorough econometric analysis are vital, as they can assist state policymakers, program
managers, and evaluators in reviewing options to reduce the economic asthma burden
in their state. A literature review performed on existing methodologies to estimate air
pollution-related health impacts and subsequent external costs found that although many
studies try to analyze the economic impact of air pollution, most end up omitting some
measurable cost components and have limitations with respect to the methods used in
estimating damage costs. We also highlight a need for increased public access to healthcare
spending data in the U.S. to encourage more research on this topic, which was an issue we
came across in our study.
The high economic cost shows the increased financial burden of air pollution and
its effects on American families and the state and national health care systems. Previous
studies have already shown the need to focus on reducing TRAP in the U.S. [15,16], a
conclusion that is further backed by this study’s results. With the high percentage of
pediatric asthma costs attributable to NO2, we are clearly highlighting how TRAP is having
a direct impact both financially and medically on children with asthma, their families, the
healthcare system, and its ancillaries, such as insurance companies in the U.S.
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